Search

Your search keyword '"Haude, Michael"' showing total 1,156 results

Search Constraints

Start Over You searched for: Author "Haude, Michael" Remove constraint Author: "Haude, Michael"
1,156 results on '"Haude, Michael"'

Search Results

2. Guideline adherence in the use of coronary angiography in patients presenting at the emergency department without myocardial infarction – Results from the German ENLIGHT-KHK project

3. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study

4. The mega COMBO collaboration: An individual patient data pooled analysis of patients undergoing PCI with COMBO stent

5. Safety and efficacy of the latest generation biodegradable polymer-coated ultrathin sirolimus-eluting stent in the treatment of coronary artery disease in a European all-comer population with or without high bleeding risk: The Cruz HBR Registry

6. Contemporary Management of Severe Symptomatic Aortic Stenosis

7. Safety and efficacy of the latest generation biodegradable polymer-coated ultrathin sirolimuseluting stent in the treatment of coronary artery disease in a European all-comer population with or without high bleeding risk: The Cruz HBR Registry.

11. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial

13. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study

15. Temporal changes in coronary plaque as assessed by an artificial intelligence–based optical coherence tomography: from the first-in-human trial on DREAMS 3G scaffold

17. Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial

19. In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris — DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial

20. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study

21. Optical Coherence Tomography Characteristics of the Novel Resorbable Magnesium Scaffold at 6 Months: An Intravascular Imaging Analysis of the First-in-Human Trial on DREAMS 3G

22. Are There Coronary Plaque Characteristics Associated With Late Lumen Loss? Artificial Intelligence-Based Optical Coherence Tomography (OCT) Study From the First-in-Human Trial on DREAMS 3G Scaffold

23. Evaluation of the guideline-adherence of coronary angiography in patients with suspected chronic coronary syndrome – Results from the German prospective multicentre ENLIGHT-KHK project

24. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial

26. Outcomes After Complex PCI With COMBO Stent Implantation: Insights from a Real-World Pooled Dataset

27. Inflow mapping method for numerical flow simulations of OCT-based patient-specific vessels using CFD

28. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial

29. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial

30. Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey

31. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk

32. CRT-100.8 Are There Coronary Plaque Characteristics Associated With Late Lumen Loss? Artificial Intelligence-Based Optical Coherence Tomography (OCT) Study From the First-in-Human Trial on DREAMS 3G Scaffold

33. CRT-600.03 Optical Coherence Tomography Characteristics of the Novel Resorbable Magnesium Scaffold at 6 Months: An Intravascular Imaging Analysis of the First-in-Human Trial on DREAMS 3G

34. Sirolimus-eluting or everolimus-eluting stents for coronary artery disease: 5-year outcomes of the randomised BIOFLOW-IV trial

36. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

37. Evaluation of the guideline-adherence of coronary angiography in patients with suspected chronic coronary syndrome – results from the German prospective multicentre ENLIGHT-KHK project

39. TCT-61 Safety and Efficacy of the Resorbable Magnesium Scaffold Magmaris in a Real-World Setting—24-Month Follow-up of the Full Cohort (2,066 subjects) of the BIOSOLVE-IV Registry

40. Bench test for magnesium scaffold

43. Comparison of everolimus-eluting bioresorbable scaffolds with everolimus-eluting metallic stents for treatment of coronary artery stenosis: Three-year follow-up of the ABSORB II randomized trial

44. Coronary Microembolization

45. The REMEDEE Trial: A Randomized Comparison of a Combination Sirolimus-Eluting Endothelial Progenitor Cell Capture Stent With a Paclitaxel-Eluting Stent

46. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis

47. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis The Task Force for the management of COVID-19 of the European Society of Cardiology

48. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

49. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

50. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic:part 2-care pathways, treatment, and follow-up

Catalog

Books, media, physical & digital resources